2024
Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes
Zhang T, Niu N, Taddei T, Jain D, Zhang X. Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes. American Journal Of Clinical Pathology 2024, aqae136. PMID: 39418121, DOI: 10.1093/ajcp/aqae136.Peer-Reviewed Original ResearchSH-HCCSteatohepatitic hepatocellular carcinomaHepatocellular carcinomaLiver diseaseHepatitis C virus infectionC virus infectionStage of fibrosisPresence of steatohepatitisOverall survivalHistological subtypesPrognostic factorsHCC subtypesBackground liverHCC casesClinicopathological featuresConventional HCCHistopathological patternsHyaline globulesTumor cellsMallory-Denk bodiesGlycogenated nucleiSteatotic liver diseaseHCCSurvival analysisSteatohepatitis
2023
Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis
Luukkonen P, Sakuma I, Gaspar R, Mooring M, Nasiri A, Kahn M, Zhang X, Zhang D, Sammalkorpi H, Penttilä A, Orho-Melander M, Arola J, Juuti A, Zhang X, Yimlamai D, Yki-Järvinen H, Petersen K, Shulman G. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2217543120. PMID: 36669104, PMCID: PMC9942818, DOI: 10.1073/pnas.2217543120.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseLiver fibrosisLiver diseaseCommon chronic liver diseaseChronic liver diseaseFatty liver diseaseRisk of fibrosisDistinct mouse modelsPyrimidine catabolismNonalcoholic steatohepatitisMouse modelTherapeutic targetFibrosisDihydropyrimidine dehydrogenaseHuman liverA variantCommon variantsMetabolomics approachDiseaseMiceInhibitionCatabolismKnockdownSteatohepatitisGimeracil
2021
Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis
González IA, Fuller LD, Zhang X, Papke DJ, Zhao L, Zhang D, Liao X, Liu X, Fiel MI, Zhang X. Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis. American Journal Of Clinical Pathology 2021, 157: 434-442. PMID: 34596220, DOI: 10.1093/ajcp/aqab142.Peer-Reviewed Original ResearchConceptsAmiodarone-induced liver injuryAlcoholic steatohepatitisScoring systemLiver injuryTest cohortDifferent histologic featuresHepatocyte ballooning degenerationMallory-Denk bodiesNeutrophilic inflammationHistologic featuresPericellular fibrosisMacrovesicular steatosisBallooning degenerationHistologic differencesLiver parenchymaCohortSteatohepatitisInjuryFurther validationInitial studyZone 1SatellitosisCholestasisSteatosisInflammation